You are here

Rituximab Proves Superior for Rare, Deadly Skin Disease

Study Data Indicate Drug May Provide Complete Remission in PV

Positive topline results from PEMPHIX, a phase 3 trial evaluating rituximab compared to mycophenolate mofetil (MMF), demonstrated rituximab’s superiority in patients with pemphigus vulgaris (PV).

Pemphigus vulgaris is a rare autoimmune disease that causes blistering on the skin and mucous membranes. Treatment is usually with corticosteroids that suppress the immune system. Left untreated, PV can be fatal. The disease can affect all races, genders, and ages, but is common in people of Mediterranean descent and middle-aged to older adults.

In PEMPHIX, a randomized, double-blind, double-dummy, active-comparator, parallel-arm, multicenter study, patients with moderate to severe, active PV requiring 60–120 mg/day oral prednisone or equivalent received either rituximab plus MMF placebo or rituximab placebo plus MMF. The primary endpoint was the proportion of patients who had sustained complete remission for at least 16 consecutive weeks at Week 52.

The secondary endpoints, cumulative corticosteroid dose, number of flares, time to sustained remission, and time to disease flare, were also met by rituximab.

Study data also indicated that rituximab may provide complete remission and a successful tapering of corticosteroid therapy that is superior to MMF in adults with PV.

Source: BioSpace, June 13, 2019

Recent Headlines

Disrupting Gut Microbiome Could Be Key
Drug Boosts Levels of Natural Endocannabinoids
Judicious Use of Antibiotics May Not Be Enough To Defeat Bacteria That Carry On By Going Into a Dormant State
KRAS Oncogene Is a Problematic Target So Researchers Are Trying Workdarounds
Understanding Neural Ensembles in Infralimbic Cortex May Lead To Improved Addiction Treatment
Vitamin E Found in Samples Around the Country
Study Links Them to Premature Death
Nag With Texting and a ‘Winners Circle’
How Serotonin and Fluoxetine Affect Microbiota Residing in the Gut